LabLogic Systems has released its Chameleon V multilabel microplate reader for researchers using fluorescence and luminescence for bio-analysis.
G-Biosciences' GET Total RNA Kit isolates total RNA from contaminating DNA, proteins, and nucleases in under 60 minutes using a simple three step protocol. The kit is compatible with numerous species and tissues.
MonoSol Rx, LLC, the developer of PharmFilm drug delivery technology, announced that it has filed a second amended complaint in its litigation against BioDelivery Sciences International, Inc. and its development partners.
Scientists have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases.
RNS60 demonstrated therapeutic benefit and proved safe at all dose levels. In a multi-dose stage of the Phase 1 study, RNS60 significantly improved peak flows and quality of life scores in patients diagnosed with stable, mild to moderate asthma.
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for marketing approval of the "Quad", a complete single-tablet regimen for the treatment of HIV-1 infection in adults.
Pfizer Inc. will discuss a few recent drug approvals, others that could get approved in the next year or two, and what will happen when Lipitor, which accounts for about one-fifth of its revenue, gets generic competition.
Momenta Pharmaceuticals Inc. won a federal court ruling that temporarily blocks other companies from selling a generic version of its anti-clotting drug.
President Barack Obama is directing the Food and Drug Administration to take steps to reduce drug shortages, an escalating problem that has endangered patients and raised the possibility of price gouging.
Researchers have developed a process to manufacture molecular weight heparin and produce a drug identical in performance and safety to the current anticoagulant fondaparinux.
Bristol-Myers Squibb and AstraZeneca announced that the U.S. Food and Drug Administration has extended the action date for dapagliflozin for the treatment of Type 2 diabetes.
The Eli Lilly and Company Foundation has committed $30 million in funding to further support The Lilly MDR-TB Partnership in its fight against multidrug-resistant tuberculosis.
A study shows that the medication, etanercept, reduces the frequency and severity of symptoms of TNF receptor-associated periodic syndrome.
BioClinica Inc.’s Express EDC is a web-based platform of an electronic data capture solution for clinical trial processes.